Interleukin 6: A biomarker for COVID-19 progression
- PMID: 35937954
- PMCID: PMC9343743
- DOI: 10.1016/j.matpr.2022.07.387
Interleukin 6: A biomarker for COVID-19 progression
Abstract
COVID-19 was discovered in China for the first time in December 2019 and was declared a pandemic by the World Health Organization on March 11, 2020. Due to its rapid geographic expansion over the last three years, it has now become a global health issue. The infection is caused by SARS-CoV-2, which is obtained from a zoonotic source and transmitted directly or through contact. Following exposure, the immune system becomes hyperactive resulting in the production of pro-inflammatory cytokines, particularly interleukin-6 (IL-6), a naturally occurring pleiotropic cytokine that plays a significant role in respiratory failure and multi-organ dysfunction. This massive inflammatory phenomenon is reminiscent of cytokine release syndrome (CRS) or "cytokine storm", which may be at the root of many severe complications. In fact, serum IL-6 levels are significantly high in patients with severe Covid-19 disease. The goal of treatment is to change the cytokine's concentration or activity. Interleukin-6 production could be inhibited, reducing inflammation and so serving as a therapeutic target. anti-interleukin-6 receptor monoclonal antibodies have been proven to reduce the severity of COVID-19 in clinical trials aimed at clarifying the function of immunoregulation. As a result, the Il-6 assay is a reliable predictor of morbidity and mortality at the time of infection diagnosis. The aim of our study is to highlight the role of interleukin 6 as biomarker of the COVID- 19 progression.
Keywords: Biomarker; COVID-19; Cytokine storm; Interleukin-6; Monoclonal antibodies; SARS-CoV-2.
Copyright © 2023 Elsevier Ltd. All rights reserved. Selection and peer-review under responsibility of the scientific committee of the Fifth edition of the International Conference on Materials & Environmental Science.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures

Similar articles
-
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.Virol J. 2020 Oct 15;17(1):154. doi: 10.1186/s12985-020-01415-w. Virol J. 2020. PMID: 33059711 Free PMC article. Review.
-
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.Int Rev Immunol. 2022;41(2):217-230. doi: 10.1080/08830185.2021.1884248. Epub 2021 Feb 22. Int Rev Immunol. 2022. PMID: 33616462 Free PMC article.
-
The roles of critical pro-inflammatory cytokines in the drive of cytokine storm during SARS-CoV-2 infection.J Med Virol. 2023 Apr;95(4):e28751. doi: 10.1002/jmv.28751. J Med Virol. 2023. PMID: 37185833 Review.
-
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).J Interferon Cytokine Res. 2023 Apr;43(4):147-163. doi: 10.1089/jir.2022.0185. J Interferon Cytokine Res. 2023. PMID: 37062817 Review.
-
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954. Rev Recent Clin Trials. 2021. PMID: 32940187 Review.
Cited by
-
Clinical Profile of SARS-CoV-2 Infection: Mechanisms of the Cellular Immune Response and Immunogenetic Markers in Patients from Brazil.Viruses. 2023 Jul 23;15(7):1609. doi: 10.3390/v15071609. Viruses. 2023. PMID: 37515295 Free PMC article.
-
Airway Epithelial-Derived Immune Mediators in COVID-19.Viruses. 2023 Jul 29;15(8):1655. doi: 10.3390/v15081655. Viruses. 2023. PMID: 37631998 Free PMC article. Review.
-
Impact of Delayed Centrifugation on Interleukin 6 Determination in Human Blood.Diagnostics (Basel). 2025 May 8;15(10):1187. doi: 10.3390/diagnostics15101187. Diagnostics (Basel). 2025. PMID: 40428180 Free PMC article.
-
An analysis of novel endothelial biomarkers to ascertain their role as prognostic indicators in severe COVID-19 illness.Indian J Med Res. 2025 Mar;161(3):298-305. doi: 10.25259/IJMR_915_2024. Indian J Med Res. 2025. PMID: 40347504 Free PMC article.
-
The role of IL-6, ferritin, and coagulopathy in Covid-19 clinical progression.F1000Res. 2023 Sep 22;11:1285. doi: 10.12688/f1000research.125115.2. eCollection 2022. F1000Res. 2023. PMID: 37841828 Free PMC article.
References
-
- Guan W., et al. China medical treatment expert group for Covid-19. Clin. Charact. Coronavirus Dis. 2019;382(18):1708–1720. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous